These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10560804)

  • 21. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
    Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
    Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis.
    van Wyk V; Badenhorst PN; Kotzé HF
    Clin Nephrol; 1997 Dec; 48(6):381-7. PubMed ID: 9438098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lepirudin in the management of patients with heparin-induced thrombocytopenia.
    Petros S
    Biologics; 2008 Sep; 2(3):481-90. PubMed ID: 19707378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient.
    Nowak G; Bucha E; Brauns I; Czerwinski R
    Wien Klin Wochenschr; 1997 May; 109(10):354-8. PubMed ID: 9200807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Corral E; Martín A; Solinís MA; Muñoz JL
    Clin Ther; 2005 Sep; 27(9):1444-51. PubMed ID: 16291417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
    Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
    Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.
    Vanholder R; Camez A; Veys N; Van Loo A; Dhondt AM; Ringoir S
    Thromb Haemost; 1997 Apr; 77(4):650-5. PubMed ID: 9134637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Laboratory assays for the evaluation of recombinant hirudin.
    Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
    Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mass transfer, clearance and plasma concentration of procalcitonin during continuous venovenous hemofiltration in patients with septic shock and acute oliguric renal failure.
    Level C; Chauveau P; Guisset O; Cazin MC; Lasseur C; Gabinsky C; Winnock S; Montaudon D; Bedry R; Nouts C; Pillet O; Benissan GG; Favarel-Guarrigues JC; Castaing Y
    Crit Care; 2003 Dec; 7(6):R160-6. PubMed ID: 14624691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticoagulation in extracorporeal circulation using recombinant hirudin: a case report.
    Beholz S; Grubitzsch H; Bergmann B; Wollert HG; Eckel L
    Perfusion; 2000 Jun; 15(3):257-60. PubMed ID: 10866429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioimmunoassay for the detection of active-site specific thrombin inhibitors in biological fluids. II. Heparin affects the binding of hirudin to alpha-thrombin.
    Lackmann M; Geczy CL
    Thromb Res; 1991 Sep; 63(6):609-16. PubMed ID: 1780805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
    Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasma.
    Hafner G; Fickenscher K; Friesen HJ; Rupprecht HJ; Konheiser U; Ehrenthal W; Lotz J; Prellwitz W
    Thromb Res; 1995 Jan; 77(2):165-73. PubMed ID: 7740508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient.
    Arzuaga A; Isla A; Gascón AR; Maynar J; Corral E; Pedraz JL
    Blood Purif; 2006; 24(4):347-54. PubMed ID: 16645266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacology of r-hirudin in renal impairment.
    Nowak G; Bucha E; Gööck T; Thieler H; Markwardt F
    Thromb Res; 1992 Jun; 66(6):707-15. PubMed ID: 1519229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beta 2-microglobulin elimination characteristics during hemofiltration with acrylonitrile and polysulfone membrane hemofilters.
    Kandus A; Ponikvar R; Drinovec J; Pavlin K; Ivanovich P
    Int J Artif Organs; 1990 Apr; 13(4):200-4. PubMed ID: 2197235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II.
    Koster A; Hansen R; Grauhan O; Hausmann H; Bauer M; Hetzer R; Kuppe H; Mertzlufft F
    J Cardiothorac Vasc Anesth; 2000 Jun; 14(3):249-52. PubMed ID: 10890474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits.
    Kouz J; Czech J; Nicolay U; Dickneite G
    Haemostasis; 1996; 26(4):179-86. PubMed ID: 8872128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular drug highlight: hirudin.
    Cheng-Lai A
    Heart Dis; 1999; 1(1):41-9. PubMed ID: 11720603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative determination of hirudin in blood and body fluids.
    Nowak G; Bucha E
    Semin Thromb Hemost; 1996; 22(2):197-202. PubMed ID: 8807717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.